Patents by Inventor Robert Falconer

Robert Falconer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11868768
    Abstract: A method for facilitating identification of secrets in source code by using machine learning is provided. The method includes retrieving a plurality of files from a repository, each of the plurality of files including a source code file; parsing the source code file to identify a training feature; associating a predetermined label with the training feature, the predetermined label corresponding to a secret label and a non-secret label; training a model by using the training feature and the corresponding predetermined label; receiving, via a graphical user interface, a test file, the test file including a set of source codes; parsing the set of source codes to identify a feature; and determining, by using the model, a first characteristic of the feature.
    Type: Grant
    Filed: September 16, 2021
    Date of Patent: January 9, 2024
    Assignee: JPMORGAN CHASE BANK, N.A.
    Inventors: Sean Moran, Ahmad Emami, Fanny Silavong, Joachim Fainberg, Ashish Tiwari, Antonios Georgiadis, Bill Moriarty, Solomon Olaniyi Adebayo, Georgios Papadopoulos, Rohan Saphal, Robert Falconer Keith, Rob Otter, Stephen Hall
  • Publication number: 20230070420
    Abstract: A method for facilitating identification of secrets in source code by using machine learning is provided. The method includes retrieving a plurality of files from a repository, each of the plurality of files including a source code file; parsing the source code file to identify a training feature; associating a predetermined label with the training feature, the predetermined label corresponding to a secret label and a non-secret label; training a model by using the training feature and the corresponding predetermined label; receiving, via a graphical user interface, a test file, the test file including a set of source codes; parsing the set of source codes to identify a feature; and determining, by using the model, a first characteristic of the feature.
    Type: Application
    Filed: September 16, 2021
    Publication date: March 9, 2023
    Applicant: JPMorgan Chase Bank, N.A.
    Inventors: Sean MORAN, Ahmad EMAMI, Fanny SILAVONG, Joachim FAINBERG, Ashish TIWARI, Antonios GEORGIADIS, Bill MORIARTY, Solomon Olaniyi ADEBAYO, Georgios PAPADOPOULOS, Rohan SAPHAL, Robert Falconer KEITH, Rob OTTER, Stephen HALL
  • Publication number: 20220202938
    Abstract: The present invention relates to a non-aqueous composition that comprises a permeation enhancer such as a terpene, for delivering an active ingredient transdermally. The composition comprises at least on one active ingredient, a terpene, and a solvent, such as a non-hydroxyl containing solvent, non-heterocyclic ester solvent and/or a tripropylene glycol alkyl ether. The composition can be used to deliver a range of actives, such as anthelmintics. The present invention provides a platform composition and can be used to deliver a wide variety of active ingredients and combinations thereof transdermally to mammals.
    Type: Application
    Filed: March 9, 2022
    Publication date: June 30, 2022
    Inventors: Laurie Robert Batt, Su Win, Keryn Davies, David Anthony Gill, James Robert Falconer, Douglas Robert Cleverly, Zimei Wu
  • Patent number: 11106458
    Abstract: Systems and methods for distributed ledger-based software supply chain management are disclosed. According to one embodiment, in an information processing apparatus comprising at least one computer processor, a method for distributed ledger-based software supply chain management may include: (1) receiving, from a software tool, a metadata artifact for a software development lifecycle event; (2) writing the metadata artifact to a metadata store; and (3) updating a present state database with values for metadata keys referencing the metadata artifact in the metadata store.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: August 31, 2021
    Assignee: JPMORGAN CHASE BANK, N.A.
    Inventors: Duncan Adams, Alex Hayzelden, Vaidyalingam Ramalingam, Trevor Collins, Andrew J. Muller, Stephen Flaherty, Tanmay Madan, Robert Falconer Keith, Ashish Tiwari
  • Patent number: 10912839
    Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: February 9, 2021
    Assignee: ELLIPSES PHARMA LIMITED
    Inventors: Robert Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
  • Publication number: 20200026510
    Abstract: Systems and methods for distributed ledger-based software supply chain management are disclosed. According to one embodiment, in an information processing apparatus comprising at least one computer processor, a method for distributed ledger-based software supply chain management may include: (1) receiving, from a software tool, a metadata artifact for a software development lifecycle event; (2) writing the metadata artifact to a metadata store; and (3) updating a present state database with values for metadata keys referencing the metadata artifact in the metadata store.
    Type: Application
    Filed: July 16, 2019
    Publication date: January 23, 2020
    Inventors: Duncan ADAMS, Alex HAYZELDEN, Vaidyalingam RAMALINGAM, Trevor COLLINS, Andrew J. MULLER, Stephen FLAHERTY, Tanmay MADAN, Robert Falconer KEITH, Ashish TIWARI
  • Patent number: 10201622
    Abstract: The present inventors have harnessed the targeting of nanoparticles to tumor sites, combined with the tumor site specific elevated MMP-14 activity within one conjugate to simultaneously deliver a vascular disrupting agent (VDA) and a MRI contrast agent to a tumor site. The MMP activatable conjugate of the present invention provides both therapeutic and diagnostic functions—and is referred to as a “theranostic”. The theranostic conjugate of the present invention achieves the benefits of tumor site specificity, VDA delivery and MRI contrast agent delivery in a single theranostic conjugate. Consequently, the present invention provides a cancer “theranostic” which improves therapeutic efficacy while simultaneously reducing dose-limiting systemic toxicities and provides a tool for rapidly and non-invasively identifying tumor location, monitoring drug delivery and pharmacodynamics.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: February 12, 2019
    Assignees: The Trustees of The Leland Stanford Junior University, Incanthera Ltd
    Inventors: Paul Loadman, Robert Falconer, Jason Gill, Jianghong Rao, Heike E. Daldrup-Link
  • Publication number: 20190015519
    Abstract: The present invention harnesses the differential expression of membrane-type matrix metalloproteinases (MT-MMPs) between human solid tumours and normal tissues to provide a systemically inactive prodrug which is selectively activated at the tumour micro-environment. The present invention provides a prodrug which is a conjugate of a taxane and a selective MT-MMP cleavable delivery vehicle.
    Type: Application
    Filed: November 29, 2016
    Publication date: January 17, 2019
    Inventors: Paul Loadman, Robert Falconer, Jason Gill
  • Publication number: 20180177886
    Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
    Type: Application
    Filed: March 1, 2018
    Publication date: June 28, 2018
    Inventors: Robert Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
  • Publication number: 20160303257
    Abstract: The present inventors have harnessed the targeting of nanoparticles to tumour sites, combined with the tumour site specific elevated MMP-14 activity within one conjugate to simultaneously deliver a vascular disrupting agent (VDA) and a MRI contrast agent to a tumour site. The MMP activatable conjugate of the present invention provides both therapeutic and diagnostic functions—and is referred to as a “theranostic”. The theranostic conjugate of the present invention achieves the benefits of tumour site specificity, VDA delivery and MRI contrast agent delivery in a single theranostic conjugate. Consequently, the present invention provides a cancer “theranostic” which improves therapeutic efficacy whilst simultaneously reducing dose-limiting systemic toxicities and provides a tool for rapidly and non-invasively identifying tumour location, monitoring drug delivery and pharmacodynamics.
    Type: Application
    Filed: July 25, 2014
    Publication date: October 20, 2016
    Applicants: University of Bradford, The Trustees of the Leland Stanford Junior University
    Inventors: Paul Loadman, Robert Falconer, Jason Gill, Jianghong Rao, Heike E. Daldrup-Link
  • Publication number: 20160008471
    Abstract: The present invention relates to a non-aqueous composition that comprises a permeation enhancer such as a terpene, for delivering an active ingredient transdermally. The composition comprises at least on one active ingredient, a terpene, and a solvent, such as a non-hydroxyl containing solvent, non-heterocyclic ester solvent and/or a tripropylene glycol alkyl ether. The composition can be used to deliver a range of actives, such as anthelmintics. The present invention provides a platform composition and can be used to deliver a wide variety of active ingredients and combinations thereof transdermally to mammals.
    Type: Application
    Filed: February 27, 2014
    Publication date: January 14, 2016
    Inventors: Laurie Robert BATT, Su WIN, Keryn DAVIES, David Anthony GILL, James Robert FALCONER, Douglas Robert CLEVERLY, Zimei WU
  • Patent number: 8927486
    Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a matrix metalloproteinase (MMP) proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: January 6, 2015
    Assignee: Incanthera Limited
    Inventors: Robert Falconer, Jason Gill, Jennifer Atkinson, Paul Loadman, Michael Bibby, Laurence Patterson
  • Patent number: 7312194
    Abstract: The invention relates to compounds which are useful in the delivery of a wide variety of therapeutically useful molecules. In particular, the invention relates to compounds which are able to act as carriers for therapeutically useful molecules, and to pharmaceutical agents comprising these carriers. The compounds of the invention comprise a mono- or oligosaccharide, a lipidic moiety, and optionally a linker and/or a spacer. The pharmaceutical agents of the invention are particularly useful for oral administration.
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: December 25, 2007
    Assignee: Alchemia Pty. Ltd.
    Inventors: Istvan Toth, Robert Falconer, Shaun Emmanuel De Cruz, Ross Peter McGeary, Benjamin Paul Ross
  • Publication number: 20040176281
    Abstract: The invention relates to compounds which are useful in the delivery of a wide variety of therapeutically useful molecules. In particular, the invention relates to compounds which are able to act as carriers for therapeutically useful molecules, and to pharmaceutical agents comprising these carriers. The compounds of the invention comprise a mono- or oligosaccharide, a lipidic moiety, and optionally a linker and/or a spacer. The pharmaceutical agents of the invention are particularly useful for oral administration.
    Type: Application
    Filed: June 30, 2003
    Publication date: September 9, 2004
    Inventors: Istvan Toth, Robert Falconer, Shaun Emmanuel De Cruz, Ross Peter McGeary, Benjamin Paul Ross
  • Patent number: 4254565
    Abstract: A method for drying, curing and mining bentonite clay in a clay pit wherein that overburden of non-clay material which may exist is removed and the surface of the bentonite ore body is tilled to loosen or break up a tier of the bentonite to expose it to the natural drying and curing effects of the atmosphere, the dried and cured tier of bentonite is removed thus exposing another tier of uncured bentonite, which is again tilled for drying and curing, and the process is repeated until the bentonite ore body is exhausted.
    Type: Grant
    Filed: November 8, 1979
    Date of Patent: March 10, 1981
    Assignee: International Minerals & Chemical Corp.
    Inventors: Jerold D. Jenkins, Robert A. Falconer, Donald A. Hentz